drugset / Trial / NCT01053936
Phase II Pharmacodynamic Trial to Determine the Effects of Bardoxolone Methyl on eGFR in Patients With Type 2 Diabetes and Chronic Kidney Disease
RandomizedParallel-groupOpen-labelTreatment
Summary
This study assesses the effects of a new formulation of bardoxolone methyl on eGFR in Patients with Chronic Kidney Disease and Type 2 Diabetes.
Timeline
- Start
- 2010-01-31
- Primary completion
- 2010-12-31
- Completion
- 2011-02-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bardoxolone methyl | Small molecule | 2.5 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 5 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 10 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 15 mg | Oral |
| Subject | Bardoxolone methyl | Small molecule | 30 mg | Oral |